California Public Employees Retirement System
RPRX icon

California Public Employees Retirement System’s Royalty Pharma RPRX Stock Holding History

California Public Employees Retirement System’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.4M Sell
828,264
-79,054
-9% -$4.11M 0.03% 375
2026
Q1 		$43.5M Sell
907,318
-134,831
-13% -$5.91M 0.03% 384
2025
Q4 		$40.3M Sell
1,042,149
-181,969
-15% -$6.94M 0.02% 427
2025
Q3 		$43.2M Sell
1,224,118
-230,082
-16% -$8.33M 0.03% 417
2025
Q2 		$52.4M Sell
1,454,200
-268,263
-16% -$8.89M 0.03% 367
2025
Q1 		$53.6M Sell
1,722,463
-58,561
-3% -$1.86M 0.04% 360
2024
Q4 		$45.4M Sell
1,781,024
-22,198
-1% -$589K 0.03% 414
2024
Q3 		$51M Sell
1,803,222
-34,116
-2% -$945K 0.04% 396
2024
Q2 		$48.5M Sell
1,837,338
-297,566
-14% -$8.25M 0.04% 390
2024
Q1 		$64.8M Sell
2,134,904
-1,995
-0.1% -$58.8K 0.05% 344
2023
Q4 		$60M Buy
2,136,899
+110,768
+5% +$3.04M 0.05% 344
2023
Q3 		$55M Buy
2,026,131
+667,827
+49% +$19.8M 0.05% 352
2023
Q2 		$41.8M Buy
1,358,304
+65,278
+5% +$2.21M 0.04% 402
2023
Q1 		$46.6M Sell
1,293,026
-88,992
-6% -$3.3M 0.04% 382
2022
Q4 		$54.6M Buy
1,382,018
+545,359
+65% +$22.8M 0.05% 373
2022
Q3 		$33.6M Buy
836,659
+216,861
+35% +$9.26M 0.03% 439
2022
Q2 		$26.1M Sell
619,798
-19,552
-3% -$802K 0.02% 481
2022
Q1 		$24.9M Sell
639,350
-53,124
-8% -$2.09M 0.02% 547
2021
Q4 		$27.6M Sell
692,474
-25,951
-4% -$1.01M 0.02% 550
2021
Q3 		$26M Buy
718,425
+3,253
+0.5% +$126K 0.02% 575
2021
Q2 		$29.3M Sell
715,172
-39,565
-5% -$1.68M 0.02% 550
2021
Q1 		$32.9M Buy
754,737
+487,417
+182% +$23.1M 0.03% 532
2020
Q4 		$13.4M Buy
267,320
+80,344
+43% +$3.41M 0.01% 842
2020
Q3 		$7.87M Buy
+186,976
New +$8.02M 0.01% 971

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

California Public Employees Retirement System's RPRX Position: Q2 2026 in Review

California Public Employees Retirement System reduced its Royalty Pharma (RPRX) stake by 8.7% in Q2 2026, selling an estimated $4.11M and leaving 828,264 shares worth $46.4M. The position accounts for 0.03% of the portfolio, ranked #375.

California Public Employees Retirement System first reported a position in RPRX in Q3 2020 and has held it in 24 quarters since. The position peaked at $64.8M in Q1 2024. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • California Public Employees Retirement System held 828,264 shares of Royalty Pharma worth $46.4M as of Q2 2026.
  • California Public Employees Retirement System sold 79,054 Royalty Pharma shares in Q2 2026, an estimated $4.11M.
  • Royalty Pharma made up 0.03% of California Public Employees Retirement System's portfolio in Q2 2026, its #375 holding.
  • California Public Employees Retirement System first reported a position in Royalty Pharma in Q3 2020 and has held it in 24 quarters since.
  • California Public Employees Retirement System's Royalty Pharma position peaked at $64.8M in Q1 2024.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on California Public Employees Retirement System's 13F filing for Q2 2026, filed 14 Aug 2026.